Evidence map›Paper›PMID 38238041›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Differences and Common Ground in

Andrea Farolfi, Wesley R Armstrong, Loic Djaileb, Andrei Gafita, Masatoshi Hotta, Martin Allen-Auerbach, Lena M Unterrainer, Wolfgang P Fendler, Matthew Rettig, Matthias Eiber and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Trial
  2. Adsorption treatment ofAnnals of nuclear medicine · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025
    Review
  11. Feasibility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  12. Impact of Posttreatment SPECT/CT on Patient Management DuringJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrea FarolfiAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wesley R ArmstrongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Loic DjailebAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Andrei GafitaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Masatoshi HottaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Lena M UnterrainerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Matthew RettigDepartment of Medicine and Urology, UCLA, Los Angeles, California.
Matthias EiberDepartment of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Boris HadaschikDepartment of Urology, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany; and.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Matthias R BenzAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; mbenz@mednet.ucla.edu.

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Positron Emission Tomography Computed TomographyPrecision MedicineEuropeGallium RadioisotopesHumansMaleUnited StatesGallium RadioisotopesPSMA-11177Lu-PSMAPET/CTprostate cancerradionuclide therapysurveytheranostic

Identifiers

PMID38238041
PMCPMC12530667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.